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Abstract 
Background: Strict glycaemic control in patients with type 2 diabetes has proven to have microvascular benefits 
while the effects on CVD and mortality are less clear, especially in high risk patients. Whether strict glycaemic control 
would reduce the risk of future CVD or mortality in patients with type 2 diabetes and pre-existing CVD, is unknown. 
This study aims to evaluate whether the relation between baseline HbA1c and new cardiovascular events or mortality 
in patients with type 2 diabetes and pre-existing cardiovascular disease (CVD) is modified by baseline vascular risk.
Methods: A cohort of 1096 patients with type 2 diabetes and CVD from the Second Manifestations of ARTerial 
Disease (SMART) study was followed. The relation between HbA1c at baseline and future vascular events (composite 
of myocardial infarction, stroke and vascular mortality) and all-cause mortality was evaluated with Cox proportional 
hazard analyses in a population that was stratified for baseline risk for vascular events as calculated with the SMART 
risk score. The mean follow-up duration was 6.9 years for all-cause mortality and 6.4 years for vascular events, in which 
period 243 and 223 cases were reported, respectively.
Results: A 1 % increase in HbA1c was associated with a higher risk for all-cause mortality (HR 1.18, 95 % CI 1.06–1.31). 
This association was also found in the highest SMART risk quartile (HR 1.33, 95 % CI 1.11–1.60). There was no relation 
between HbA1c and the occurrence of cardiovascular events during follow-up (HR 1.03, 95 % CI 0.91–1.16). The inter-
action term between HbA1c and SMART risk score was not significantly related to any of the outcomes.
Conclusion: In patients with type 2 diabetes and CVD, HbA1c is related to the risk of all-cause mortality, but not to 
the risk of cardiovascular events. The relation between HbA1c and all-cause mortality in patients with type 2 diabetes 
and vascular disease is not dependent on baseline vascular risk.
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Background
Cardiovascular disease (CVD) is a major healthcare prob-
lem [1], especially in high income countries [2, 3], and it 
remains the most common cause of death and disability 
in patients with type 2 diabetes [4]. As the number of 
patients with type 2 diabetes is expected to grow to 592 
million worldwide by 2035 [5], it is relevant to expand the 
understanding of the role of type 2 diabetes in the devel-
opment and progression of CVD.
In cohort studies with patients with type 2 diabe-
tes, poor glycaemic control, as measured by HbA1c, 
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is associated with an increased risk for cardiovascu-
lar disease [6–8]. The relationship between increas-
ing plasma HbA1c levels and a higher risk for incident 
macrovascular and microvascular disease is most 
prominent above a HbA1c of 7.0 % (53 mmol/mol) for 
macrovascular and 6.5 % (48 mmol/mol) for microvas-
cular disease [9].
In clinical trials, lowering HbA1c levels in patients 
with type 2 diabetes has beneficial effects on incident 
microvascular complications [10–12], while the effect 
on macrovascular complications is less clear [10–13]. 
Follow-up analyses of these trials display positive effects 
of strict glycaemic control [14–16] as well as the absence 
of such benefits [14, 17] or even adverse effects [16]. 
Recent meta-analyses seem to support the more negative 
results and state that strict glucose regimes might not be 
the optimal treatment to reduce vascular risk for patients 
with type 2 diabetes [18, 19].
It has been suggested that these different findings 
might be explained by differences in patient character-
istics between the studies [20]. It seems that healthier 
patients (younger, shorter history of CVD and/or type 
2 diabetes, lower HbA1c at baseline) benefit more 
from strict glycaemic control than their older coun-
terparts with a longer history of disease (CVD and/
or type 2 diabetes) and a higher baseline HbA1c [13, 
15–17].
These findings suggest that strict glycaemic control 
might not be beneficial in high risk patients, including 
patients with type 2 diabetes and cardiovascular disease 
[20]. However, little is known about the relation between 
HbA1c and risk for new cardiovascular events in these 
high risk patients [21]. As patients with type 2 diabetes 
and pre-existing CVD are at very high risk for new car-
diovascular events and death, it is relevant to investigate 
whether glycaemic control remains an important amend-
able risk factor in these patients.
The recently published SMART (Second Manifesta-
tions of ARTerial Disease) risk score predicts 10-year risk 
of recurrent major vascular events and vascular mortality 
in patients with cardiovascular disease [22]. Their work 
showed that patients with a history of cardiovascular 
disease do not, as was previously assumed, always clas-
sify as high-risk patients (defined as having a 10-year risk 
of above 20  %), as the 10-year risk for recurrent events 
in their cohort ranged from 6 to 44 % [22]. The SMART 
risk score enables clinicians to quantify risk in individ-
ual patients and to identify those at the highest risk. We 
therefore investigated the relation between HbA1c and 
new cardiovascular events and mortality in patients with 
type 2 diabetes and CVD, stratified by their baseline risk 
for new cardiovascular events and mortality as calculated 
by the SMART risk score.
Methods
Study population
For this study we used data from patients with type 2 
diabetes and cardiovascular disease enrolled in the 
Second Manifestations of ARTerial Disease (SMART) 
cohort. The design and rationale of the SMART study 
have been described previously [23]. To shortly sum-
marise, patients aged 18–79 who are referred to the 
University Medical Center Utrecht with atherosclerotic 
vascular disease or for treatment of cardiovascular risk 
factors are included in the database. Physical and labo-
ratory examinations are performed in the hospital after 
an at least 8-h fast. Information about a history of CVD, 
vascular risk factors and a detailed medical history are 
obtained via a questionnaire. Follow-up information 
is obtained via questionnaires sent to patients every 
6  months or via the general practitioner (GP) if the 
patient is unwilling to fill out questionnaires and gives 
consent for GP consulting. The ethics committee of the 
University Medical Center Utrecht approved this study, 
all eligible patients received written and oral informa-
tion about the study and all included participants gave 
informed consent [23].
For the current study, patients with type 2 diabetes 
and clinically manifest vascular disease at baseline were 
selected (n  =  1205). Patients with a missing high-sen-
sitivity C-reactive protein (hsCRP) value (n  =  22) or a 
hsCRP value above 15 mg/L (n = 83) were excluded. The 
latter were excluded because we think such a high hsCRP 
value is more indicative of infection or a different cause 
of inflammation than the low-grade inflammation seen 
in patients with atherosclerosis [24]. Finally, we recalcu-
lated missing data regarding LDL using the Friedewald 
formula. Data that remained missing after this proce-
dure (n = 6) was imputed. The participants for whom the 
SMART risk score could not be calculated (n = 4) were 
also excluded, bringing the final study population to 1096 
participants.
Study definitions
Diabetes mellitus was defined as a referral diagnosis of 
type 2 diabetes, self-reported type 2 diabetes, a fasting 
serum glucose ≥7.0  mmol/l at inclusion with initiation 
of glucose lowering treatment within 1  year or the use 
of oral anti-hyperglycemic agents or insulin at baseline. 
Participants with known type 1 diabetes were excluded 
from our analyses. History of clinically manifest vascu-
lar disease is defined as ever having had clinical manifest 
vascular disease [23]. HbA1c was studied as a continuous 
variable.
The cardiovascular outcomes defined are myocardial 
infarction (MI), ischemic stroke, the composite of major 
cardiovascular events, cardiovascular mortality, and 
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all-cause mortality. Their definitions have been described 
elsewhere [23]. Each notification of a possible event is 
thoroughly checked by collecting all available informa-
tion about the patient regarding the event. This includes 
all correspondence and documented investigations con-
cerned with the particular event. All events were audited 
by three independent committee members of the Out-
come Committee.
Data analyses
Data are presented as mean ±  standard deviation (SD) 
or median with interquartile range for variables with 
a skewed distribution. For all 1096 participants, the 
SMART risk score was calculated using the equation 
described by Dorresteijn et  al. [22]. This equation pre-
dicts the 10-year risk of recurrent major vascular events 
(myocardial infarction, stroke and vascular death) in 
patients with CVD [22]. All analyses were performed for 
the whole cohort and in quartiles (Q1-Q4) of SMART 
risk. Non-HDL cholesterol was calculated for all patients 
by subtracting the measured HDL cholesterol from the 
measured total cholesterol value. To assess whether 
baseline risk as defined by the SMART risk score has 
a modifying effect on the relation between HbA1c and 
new outcomes, the interaction term between HbA1c 
and SMART risk score was used. We considered the 
effect modification by the SMART risk score signifi-
cant when the p value of the interaction term was <0.05. 
Cox regression modelling was used to assess the rela-
tion between HbA1c and cardiovascular outcomes and 
mortality. Cubic spline analysis was rejected based on 
the inability of this technique to measure effect modi-
fication. Results are given as hazard ratios with 95  % 
confidence interval, and denote the increase in risk for 
a cardiovascular outcome or mortality related to a 1  % 
increase in HbA1c. Three models were constructed. The 
first model was a univariate model which only included 
HbA1c. The second model was adjusted for sex and 
age, and the third model was additionally adjusted for 
the known confounders current smoking, non-HDL 
cholesterol, diabetes duration, systolic blood pressure 
and eGFR (MDRD). We performed sensitivity analyses 
including the earlier excluded patients with a hsCRP 
value above 15  mg/L (n  =  83) and additional analyses 
adjusted for all components of the SMART risk score. 
All analyses were performed in an imputed dataset, as 
missing data is seldom missing at random. We imputed 
missing data on eGRF(1, 0.09  %), LDL cholesterol (6, 
0.5  %) and HbA1c (100, 9.1  %). All analyses were per-
formed using SPSS 21 (IBM, New York). Graphs were 




The mean age of the participants in the cohort was 
62.6 ± 8.8 years and 76 % of the participants were male. 
The SMART risk score ranged from a predicted 5–100 % 
10-year risk for recurrent vascular events. The creation of 
quartiles based on the SMART risk score resulted in four 
groups with a SMART risk score range of 5–16, 16–24, 
24–37 and 37–100 % respectively (Table 1).
Mean age increased from 55.8 ± 7.1 years in the low-
est risk quartile to 70.0  ±  6.5  years in the highest risk 
quartile, and the percentage of males increased from 
72 to 76  %. In addition, the mean duration of diabetes 
increased from 4.0 to 6.0 years and time since first vascu-
lar event increased from 0 to 9 years.
The relation between HbA1c and risk for new 
cardiovascular events and mortality in the whole cohort
During a mean follow-up period of 6.9 years 243 patients’ 
deaths were reported. The mean follow-up period for vas-
cular events was 6.4 years, in which period 223 cases were 
reported. The separate outcomes had follow-up periods of 
5.8 years for MI and 6.7 years for stroke, in which period 
84 and 48 events were reported, respectively.
In the whole cohort of patients with type 2 diabetes 
and vascular disease, a 1 % increase in HbA1c level was 
associated with a higher risk for all-cause mortality (HR 
1.18, 95 % CI 1.06–1.31). There was no relation between 
HbA1c and risk for new cardiovascular events during fol-
low-up (HR 1.03, 95 % CI 0.91–1.16) (Table 2).
The relation between HbA1c and new cardiovascular 
events and mortality according to baseline risk
In patients with the highest predicted 10  years risk for 
new cardiovascular disease or mortality (37–100  %), a 
1 % increase in HbA1c was associated with an increased 
risk for cardiovascular mortality (HR 1.29, 95 % CI 1.03–
1.61) and all-cause mortality (HR 1.33, 95  % CI 1.11–
1.60) (Table  2). The results for the lowest SMART risk 
quartile were similar, albeit not significant (HR 1.36, 95 % 
CI 0.93–1.98). An inverse relation was suggested between 
HbA1c and risk for MI in all quartiles (Fig. 1). This was 
most apparent in the second risk quartile (HR 0.71, 95 % 
CI 0.46–1.10).
However, the interaction term between HbA1c and 
the SMART risk score was not significant for the com-
posite cardiovascular outcomes and for cardiovascular or 
all-cause mortality (p = 0.225, p = 0.259 and p = 0.179 
respectively). Thus, baseline risk as estimated by the 
SMART risk score did not modify the relation between 
HbA1c and cardiovascular events or mortality in patients 
with type 2 diabetes and cardiovascular disease.
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None of our sensitivity analyses changed the direction 
or magnitude of the modifying effect of the SMART risk 
score on the relation between HbA1c and vascular out-
comes and mortality.
Discussion
In the present study we show that within a population 
of patients with type 2 diabetes and CVD at baseline, 
an increase in HbA1c is related to an increased risk for 
Table 1 Baseline characteristics of the whole cohort and stratified by vascular risk
Whole cohort Q1 Q2 Q3 Q4
n = 1072 n = 268 n = 268 n = 269 n = 268
SMART risk score (% 10 year risk for recurrent vascular events) 5–16 16–24 24–37 37–98
Age (years) 62.6 ± 8.8 55.8 ± 7.1 60.0 ± 7.7 64.5 ± 7.0 70.0 ± 6.5
Male sex (n, %) 817 (76) 194 (72) 214 (80) 206(77) 203 (76)
Duration of diabetes (years) 4.0 (1.0–10.0) 4.0 (1.0–9.0) 4.0 (1.0–9.0) 4.0 (1.0–12.0) 6.0 (1.0–12.0)
HbA1c (%) 6.9 (± 1.1) 6.7 (± 1.0) 7.0 (± 1.3) 6.9 (± 1.1) 7.0 (± 1.1)
HbA1c converted (mmol/mol) 52 50 53 52 53
Fasting blood glucose (mmol/L) 7.9 (6.7–9.5) 7.6 (6.5–8.9) 8.2 (7.0–10.0) 7.7 (6.8–9.3) 7.9 (6.7–9.7)
Total cholesterol (mmol/L) 4.6 ± 1.2 4.2 ± 1.0 4.5 ± 1.1 4.6 ± 1.2 5.0 ± 1.3
HDL-cholesterol (mmol/L) 1.1 ± 0.3 1.2 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.3
LDL-cholesterol (mmol/L) 2.6 ± 1.0 2.2 ± 0.8 2.5 ± 1.0 2.7 ± 1.0 2.9 ± 1.2
Triglycerides (mmol/L) 1.9 ± 1.2 1.7 ± 1.1 1.9 ± 1.1 2.0 ± 1.2 2.1 ± 1.2
non-HDL-cholesterol (mmol/L) 3.31 (2.67–4.17) 2.90 (2.34–3.54) 3.27 (2.66–4.06) 3.48 (2.87–4.31) 3.67 (2.93–4.81)
eGFR (MDRD) 76 ± 21 85 ± 14 83 ± 18 74 ± 21 61 ± 20
Systolic blood pressure (mmHg) 145 ± 21 137 ± 18 144 ± 19 147 ± 22 152 ± 21
Diastolic blood pressure (mmHg) 81 ± 11 81 ± 10 82 ± 11 82 ± 12 79 ± 11
Weight (kg) 85.6 ± 14.9 85.8 ± 15.5 87.2 ± 15.6 86.6 ± 14.3 83.0 ± 13.8
BMI (kg/m2) 28.4 ± 4.1 28.3 ± 4.1 28.8 ± 4.6 28.6 ± 4.0 27.7 ± 3.7
Current smoking (n,  %) 268 (25) 42 (17) 65 (24) 86 (32) 75 (28)
Microalbuminuria (n, %) 250 (23) 39 (15) 53 (20) 71 (26) 87 (33)
hs-CRP (mg/L) 2.1 (1.0–4.4) 1.1 (0.6–2.3) 2.1 (1.0–4.3) 2.4 (1.4–4.8) 3.4 (1.8–5.7)
Lipid-lowering treatment (n, %)
 Statins 784 (73) 209 (78) 164 (61) 155 (58) 144 (54)
Glucose-lowering treatment (n, %)
 Only lifestyle/diet treatment 233 (22) 49 (18) 71 (27) 57 (21) 56 (21)
 Oral treatment 690 (64) 180 (67) 167 (62) 171 (64) 172 (64)
 Insulin use 266 (25) 66 (25) 58 (22) 31 (11) 30 (11)
 Combination of oral treatment and insulin 116 (11) 27 (10) 28 (10) 24 (9) 27 (10)
Blood pressure medication (n, %)
 β-blockers 616 (57) 184 (69) 149 (56) 145 (54) 138 (52)
 Diuretics 371 (35) 65 (24) 82 (31) 104 (39) 120 (45)
 ACE inhibitors 444 (41) 112 (46) 103 (38) 108 (40) 111 (41)
 Calcium antagonists 277 (26) 58 (22) 73 (27) 67 (25) 79 (30)
 Angiotensin II receptor blockers 175 (16) 35 (13) 34 (13) 57 (21) 49 (18)
Antithrombotic therapy (n, %)
 Thrombocyte aggregation inhibitor 833 (78) 223 (83) 208 (78) 202 (75) 200 (75)
 Oral anticoagulants 153 (14) 26 (10) 28 (10) 36 (13) 63 (24)
Years since first vascular event 1 (0–9) 0 (0–1) 0 (0–6) 1 (0–10) 9 (1–18)
Location of vascular disease (n, %)
 Cerebrovascular disease 312 (29) 40(15) 59 (22) 75 (28) 138 (49)
 Coronary artery disease 734 (68) 215 (80) 188 (70) 167 (62) 164 (61)
 Peripheral artery disease 219 (20) 18 (7) 47 (18) 62 (23) 92 (34)
 Abdominal aortic aneurysm 73 (7) 1 (0.4) 4 (1.5) 20 (7.4) 48 (18)
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all-cause mortality, but not to an increased risk for car-
diovascular events. The relation between HbA1c and risk 
for all-cause mortality is not significantly influenced by 
baseline vascular risk.
The Veterans Affairs Diabetes Trial (VADT) study also 
stratified their patients with type 2 diabetes, of which 
38 % had CVD at baseline, by baseline risk, using coro-
nary artery calcium (CAC) as a measure for atheroscle-
rosis [25]. Strict glycaemic control was related to lower 
incidence of future cardiovascular events in patients 
with a CAC score below 100 at baseline, while this effect 
was not present in patients with higher CAC values [25]. 
Although not directly comparable to our study due to 
the interventional nature of the VADT, these findings do 
suggest that within a high risk population, the relation 
between glycaemic control and cardiovascular events dif-
fers according to risk for (new) cardiovascular events.
The absence of a relation between HbA1c and (new) 
vascular disease in our study population could be related 
to differences in the pathogenesis of vascular disease in 
patients with type 2 diabetes. In the later stages of type 
2 diabetes other risk factors than glycaemic control may 
be more important in inducing vascular complications. 
These include hypertension [26, 27], lipids [28, 29], and 
the calcification of the intima media of blood vessels, 
called Mönckeberg’s sclerosis [30]. The latter condition is 
strongly associated with morbidity and mortality in dia-
betes and is independent of glycaemic control [30].
Following this line of reasoning, the significant relation 
between HbA1c and mortality in the whole cohort is an 
unexpected finding. This result may be powered by the 
patients in the highest risk quartile, who are older and 
have a longer history of vascular disease and diabetes. In 
this group of high risk patients, a high HbA1c may be a 
proxy of frailty. Indeed, higher HbA1c levels are related 
to a higher chance of being frail in women, and this rela-
tion is strongest above an HbA1c level of 9 % (75 mmol/
mol) [31]. Frailty in patients with diabetes is associated 
with higher mortality and glucose dysregulation [32], and 
the prevalence of frailty increases with age.
We propose that in the highest risk quartile, HbA1c 
might be regarded as a proxy for overall health status or 
frailty. High HbA1c levels would then reflect a poor overall 
health status, which in itself can be regarded as a risk fac-
tor for mortality. Although the whole study population had 
a mean HbA1c of 51.9 mmol/mol, there was a significant 
Table 2 The relation between HbA1c and risk for new cardiovascular events or mortality in the whole cohort and in quar-
tiles stratified by vascular risk
The relation between HbA1c and risk for each outcome under study is represented separately. Model I is the crude model, Model II is adjusted for sex and age, and 
Model III is additionally adjusted for current smoking, non-HDL cholesterol, diabetes duration, systolic blood pressure and eGFR (MDRD). The hazard ratios are given 
per 1 % HbA1c. For example, in the patients of this cohort a 1 % higher HbA1c is associated with a 1.18-fold higher risk of all-cause mortality
Whole cohort Q1 Q2 Q3 Q4
n = 1096 n = 274 n = 274 n = 274 n = 274
SMART risk score (% 10 year risk for recurrent vascular events) 5–16 16–24 24–37 37–100
All-cause mortality 243 events 21 events 39 events 66 events 117 events
Model I 1.13 (1.02–1.24) 1.42 (0.99–2.04) 1.11 (0.90–1.37) 1.00 (0.82–1.22) 1.23 (1.04–1.46)
Model II 1.21v (1.09–1.34) 1.57 (1.10–2.25) 1.09 (0.87–1.36) 1.04 (0.85–1.27) 1.28 (1.08–1.53)
Model III 1.18 (1.06–1.31) 1.36 (0.93–1.98) 1.04 (0.82–1.33) 1.00 (0.80–1.24) 1.33 (1.11–1.60)
Composite vascular outcome 223 events 28 events 46 events 53 events 96 events
Model I 1.03 (0.92–1.15) 1.23 (0.89–1.70) 0.89 (0.70–1.14) 0.90 (0.71–1.13) 1.18 (0.98–1.42)
Model II 1.07 (0.96–1.20) 1.31 (0.94–1.83) 0.93 (0.73–1.20) 0.94 (0.74–1.19) 1.19 (0.99–1.43)
Model III 1.03 (0.91–1.16) 1.17 (0.83–1.67) 0.92 (0.71–1.20) 0.88 (0.68–1.15) 1.20 (0.99–1.46)
Myocardial infarction 84 events 15 events 23 events 23 events 23 events
Model I 0.88 (0.72–1.08) 0.86 (0.50–1.49) 0.70 (0.47–1.06) 0.94 (0.70–1.32) 1.02 (0.68–1.53)
Model II 0.88 (0.72–1.09) 0.87 (0.50–1.52) 0.71 (0.47–1.08) 0.99 (0.70–1.40) 0.99 (0.66–1.49)
Model III 0.87 (0.71–1.07) 0.92 (0.51–1.65) 0.71 (0.46–1.10) 1.01 (0.69–1.48) 0.99 (0.66–1.47)
Ischemic stroke 48 events 5 events 10 events 9 events 24 events
Model I 1.10 (0.88–1.39) 1.57 (0.81–3.01) 1.09 (0.70–1.70) 0.66 (0.34–1.29) 1.25 (0.88–1.79)
Model II 1.16 (0.92–1.48) 1.72 (0.87–3.40) 1.22 (0.77–1.95) 0.64 (0.33–1.25) 1.27 (0.89–1.83)
Model III 1.09 (0.84–1.41) 2.13 (0.79–5.75) 1.28 (0.77–2.13) 0.60 (0.31–1.19) 1.26 (0.86–1.85)
Cardiovascular mortality 140 events 11 events 22 events 30 events 77 events
Model I 1.07 (0.94–1.23) 1.41 (0.85–2.35) 0.91 (0.64–1.29) 0.97 (0.72–1.30) 1.21 (0.98–1.49)
Model II 1.15 (1.00–1.32) 1.62 (1.00–2.62) 0.92 (0.64–1.31) 1.00 (0.74–1.34) 1.24 (1.00–1.54)
Model III 1.09 (0.94–1.27) 0.97 (0.59–1.60) 0.79 (0.52–1.21) 0.94 (0.67–1.31) 1.29 (1.03–1.61)
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distribution of HbA1c levels (range 29–116.4 mmol/mol) 
in the whole cohort. While it is quite possible that the rela-
tion between HbA1c and endpoints is different in very 
high HbA1c levels (for example >100  mmol/mol), our 
study lacks the statistical power to address this question. 
In that regard, our study population is an example of a 
cohort of patients with type 2 diabetes and cardiovascular 
disease which is comparable to patient population typically 
seen in an everyday out-patient clinic.
The main strengths of this study include the prospec-
tive design, the substantial follow-up period and large 
cohort size providing a relatively high number of events. 
Furthermore, the completeness of data reduced the risk 
of bias. The use of the SMART risk score, which was 
derived from the SMART cohort, ensured that the risk 
score used was well suited for the dataset. However, 
it should be noted that this score is not yet externally 
validated.
Several limitations of this study need to be addressed. 
The size of the study population limited the amount of 
analyses we could perform. As a result of the stratifica-
tion we performed, some outcomes lost analytic power. 
Fig. 1 The relation between HbA1c and risk for new cardiovascular events or mortality in quartiles stratified by baseline risk. The relation between 
HbA1c and risk for each outcome under study is represented separately. The quartiles are denoted on the x axis with Q1–Q4 respectively. The 
SMART risk score range of each quartile is given between brackets. Hazard ratios are adjusted for sex, age, current smoking, non-HDL cholesterol, 
diabetes duration, systolic blood pressure and eGFR (MDRD). Figure 1a–e show the association between the SMART risk score and risk for a speci-
fied cardiovascular event (b, c, d) or mortality (a, e). The SMART risk score calculates the 10-year risk for developing a new cardiovascular event in 
patients with a history of cardiovascular disease. For example, a person with a SMART risk score of 20 has a 20 % chance of experiencing a new 
cardiovascular event in the upcoming 10 years
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This was specially the case for the lower risk quartiles, 
in which few events occurred during the study period. 
Validation of our findings in larger cohorts would aid 
to support our conclusions. As the current study was 
conducted in an observational cohort, no conclusions 
regarding treatment effects could be made. In addition, 
limited information about microvascular outcomes was 
available and these could therefore not be addressed in 
the current study. Our suggestion of a link with frailty 
could not be supported by our data due to the absence 
of data on frailty status. As precise information on non-
cardiovascular causes of death was lacking, we could 
not evaluate whether the relation between HbA1c and 
all-cause mortality might still be powered by presumed 
diabetes-related non-cardiovascular cause of death 
like cirrhosis associated with non-alcoholic fatty liver 
disease.
Conclusions
In conclusion, in patients with type 2 diabetes and CVD, 
HbA1c is related to the risk of all-cause mortality, but not 
to the risk of cardiovascular events. The relation between 
HbA1c and all-cause mortality in patients with type 2 
diabetes and vascular disease is not dependent on base-
line vascular risk.
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